Accurate determination of vismodegib (VISMO), a Hedgehog pathway inhibitor approved for the management of basal cell carcinoma and other malignancies, is essential for pharmacokinetic assessment, dose optimization, and therapeutic drug monitoring.
Alaseem et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: